Sionna Therapeutics, Inc.
corporate_fare Company Profile
Sionna Therapeutics, Inc. (NASDAQ:SION) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for SION at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 10/10, with 5 rated 8 or above. Recent SEC coverage for SION spans 8-K, 144, 10-Q, 144/A.
Recent high-impact activity:
- SION-719 Fails Phase 2a Endpoint; Price Target Cut to $15.33
- Sionna Posts $32.4M Q3 Loss; $249.8M Cash Funds Operations Into 2H 2029
- RA Capital Files to Sell $21.8M of Sionna Shares
- Sionna Cuts 46% of Staff, Pivots to CF Combo After Lead Drug Fails
- Sionna Cuts 46% of Workforce, Pivots to SION-451 + SION-2222 Dual Combo After SION-719 Failure
Financial Snapshot
Short Interest & Short Volume
4.10 days to coverFINRA reported short interest of 4,212,186 shares in SION as of the October 30, 2026 settlement, a 14.6% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 20, 2026, 50.0% of SION volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.